2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Vaccines, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Biological Processes, Apoptosis, Metabolism, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Study Population, Human, Adult, Elderly
PAPER

5150 Long-term Phase 2 results from the EVICTION trial of IPN60340 with azacitidine-venetoclax in newly diagnosed acute myeloid leukemia

Abhishek Maiti, MBBS, Pierre-Yves Dumas, MD, PhD2, Pierre Peterlin, MD3, Daniel Morillo, MD4, Jose Miguel Torregrosa Diaz, MD5, Aude de Gassart6, Maelle Mairesse7, George Saad8, Noemi Angelosanto9, Jianming Wang10, Rajat Bannerji, MD, PhD11, Ivan Diaz-Padilla12, Sylvain Garciaz, MD13
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
3 Nantes University Hospital, Nantes, France
4 START Madrid-FJD Early Phase Trials Unit, Madrid, Spain
5 Poitiers University Hospital, Poitiers, France
6 ImCheck Therapeutics, Marseille, France
7 ImCheck Therapeutics, Marseille, France
8 ImCheck Therapeutics, Marseille, France
9 ImCheck Therapeutics, Marseille, France
10 Ipsen, Cambridge, Massachusetts, United States
11 Ipsen, Cambridge, Massachusetts, United States
12 Ipsen, Zug, Switzerland
13 Aix-Marseille University, Marseille, France

Introduction:
Azacitidine–venetoclax (Aza-Ven) is an approved first-line treatment for patients with newly diagnosed acute myeloid leukemia (ND-AML) who are unfit for intensive chemotherapy (IC). IPN60340, formerly ICT01, is a first-in-class, humanized anti‑BTN3A monoclonal antibody that selectively activates γ9δ2 T cells. The phase 1/2a EVICTION trial (NCT04243499) evaluated whether IPN60340 can be safely combined with Aza-Ven and whether it improves anti‑leukemic activity in patients ineligible for IC. Previously presented results supported the choice of IPN60340 10 mg administered intravenously every 4 weeks (Q4W) as the recommended phase 2 dose (RP2D). Here, phase 2 results at median follow-up of 16.2 months for IPN60340 10 mg are presented alongside evaluation of the European LeukemiaNet (ELN) 2024 prognostic subgroups.

Methods:
Data are presented from the phase 2 component of the multi-cohort, worldwide, multi‑center, single-arm EVICTION trial which enrolled ND-AML patients ineligible for IC, including patients ≥18 years old with comorbidities or those ≥75 years old. During dose‑selection, patients were randomized to low‑dose (10 mg) or high‑dose (75 mg) IPN60340 in combination with standard Aza-Ven Q4W. IPN60340 10 mg Q4W was selected as the RP2D, assessed in a dose-expansion cohort. The primary objective for the dose‑expansion cohort was to assess the proportion of patients achieving complete remission (CR) according to the ELN 2022 criteria. Secondary objectives assessed at follow‑up included duration of CR (DoCR) and overall survival (OS). Data are presented as intention-to-treat. Safety findings assessed included adverse events (AEs) ≥Grade 3 and AEs of special interest (AESI) such as cytokine release syndrome (CRS) and infusion related reactions (IRR).

Results:
From September 23, 2023, to March 16, 2025, 41 patients were enrolled to receive IPN60340 10 mg, including 19 in the dose-selection cohort and 22 in the dose-expansion cohort. Among all patients treated with IPN60340 10 mg, the median age was 75 years (range, 51–87), 32% had adverse-risk AML per ELN 2024 classification and 7% went to allogeneic hematopoietic stem cell transplantation. At data cut-off (May 6, 2026), 68% of patients achieved CR (95% confidence interval [CI], 51.9%–81.9%), 2% achieved CR with partial hematologic recovery (CRh), and 2% achieved CR with incomplete hematologic recovery (CRi), for a composite CR (CRc) rate of 73%. For all patients treated with IPN60340 10 mg after a median follow-up of 16.2 months (95% CI: 11.5–19.4), median DoCR (95% CI: 11.2–not evaluated [NE]) and median duration of composite CR (DoCRc; 95% CI: 10.3–NE) were not reached. Median OS (95% CI: 10.4–NE) was not reached and one-year OS was 60.3% (95% CI: 45.8–79.5). Median time to CRc response was 0.9 months (95% CI: 0.7–1.8). Local minimal residual disease (MRD) results were available for 15 patients; 73% were MRD-negative. The CR rate was 74% in TP53 wild-type (wt) patients and 54% in TP53-mutant (mt) patients. Median DoCR and DoCRc was 9.5 months (95% CI: 5.1–NE) for TP53-mt patients. Median survival was not reached in TP53 wt patients and was 6.9 months (95% CI: 3.9–NE) in TP53-mt patients. For all patients treated with IPN60340 10 mg, 40 patients (98%) experienced at least one Grade ≥3 treatment-emergent AE; the most common were thrombocytopenia (65.9%), neutropenia (63.4%), febrile neutropenia (43.9%) and anemia (24.4%). IPN60340 dose interruptions occurred in 13 patients (32%), and IPN60340 discontinuations occurred in 6 patients (15%). AEs leading to treatment discontinuation were not considered related to IPN60340. AESIs of CRS/IRR were reported in 4 patients (10%); one event was serious, and none led to treatment discontinuation. A single Grade 3 CRS AE occurred without premedication, while all subsequent CRS and IRR events were Grade 1–2 with premedication and occurred only during cycle 1.

Conclusions:
In ND-AML patients ineligible for IC, IPN60340 plus Aza-Ven showed high rated of durable CR (CR rate: 68%; median not reached) and median OS was not reached after 16.2 months’ follow-up. No significant added toxicity was observed beyond that expected with Aza-Ven, the current first-line standard of care. These findings support continued development of IPN60340, which has Breakthrough Therapy Designation and a randomized Phase 2/3 trial planned to further assess clinical benefit. Updated results will be provided at the time of presentation.

Pierre-Yves Dumas, MD, PhD: BMS - Research Funding; Sanofi - Research Funding; Servier - Research Funding; Daiichi-Sankyo - Research Funding; IQVIA - Research Funding; Roche - Research Funding; Janssen - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Gilead - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Jazz Pharmaceutical - Consultancy (Includes expert testimony); Novartis, Astellas, Daiichi-Sankyo, Abbvie, Servier, BMS, Jazz Pharmaceutical, Janssen, AstraZeneca - Consultancy (Includes expert testimony); Daiichi-Sankyo - Consultancy (Includes expert testimony)